A Case Report of a 37-Year-Old Alzheimer’s Disease Patient with Prominent Striatum Amyloid Retention
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
With recent advancement in amyloid imaging, diagnostic application of this new modality has become a great interest among researchers. New ligands, such as 18F- florbetaben, florbetapir and flutemetamol, have been discovered to overcome limitations of preexisting ligand Pittsburgh compound B. We report here a case of a 37-year-old male patient whose initial complaints comprised of gradual cognitive decline, apraxia, disorientation and sleep disturbances. 18F-Florbetaben amyloid imaging of the patient showed diffuse amyloid retention with prominent striatal uptake. This finding supports the clinical utility of amyloid imaging in diagnostic process of early-onset AD. Moreover, striatal dominant uptake pattern demonstrated in this patient include some meaningful clinical implications that warrant special attention among clinicians.
Abstract
With recent advancement in amyloid imaging, diagnostic application of this new modality has become a great interest among researchers. New ligands, such as 18F- florbetaben, florbetapir and flutemetamol, have been discovered to overcome limitations of preexisting ligand Pittsburgh compound B. We report here a case of a 37-year-old male patient whose initial complaints comprised of gradual cognitive decline, apraxia, disorientation and sleep disturbances. 18F-Florbetaben amyloid imaging of the patient showed diffuse amyloid retention with prominent striatal uptake. This finding supports the clinical utility of amyloid imaging in diagnostic process of early-onset AD. Moreover, striatal dominant uptake pattern demonstrated in this patient include some meaningful clinical implications that warrant special attention among clinicians.
참고문헌 (24)
- Selkoe DJ, "The amyloid hypothesis of Alzheimer’s disease at 25 years", EMBO Mol Med, 8, pp.595~608 (2016)
- Jack CR Jr, "Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade", Lancet Neurol, 9, pp.119~128 (2010)
- Rabinovici GD, "The translational journey of brain β-amyloid imaging : from positron emission tomography to autopsy to clinic", JAMA Neurol, 72, pp.265~266 (2015)
- Bensaïdane MR, "Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers", J Alzheimers Dis, 52, pp.1251~1262 (2016)
- Klunk WE, "Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B", Ann Neurol, 55, pp.306~319 (2004)
- Villemagne VL, "Amyloid imaging with(18)F-florbetaben in Alzheimer disease and other dementias", J Nucl Med, 52, pp.1210~1217 (2011)
- Braak H, "Frequency of stages of Alzheimer-related lesions in different age categories", Neurobiol Aging, 18, pp.351~357 (1997)
- Handen BL, "Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B", Alzheimers Dement, 8, pp.496~501 (2012)
- Lao PJ, "The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B", Alzheimers Dement, 12, pp.380~390 (2016)
- Morris JC, "Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type", Int Psychogeriatr, 9(Suppl 1), pp.173~176 (1997)
- O’Bryant SE, "Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores : a Texas Alzheimer’s research consortium study", Arch Neurol, 65, pp.1091~1095 (2008)
- Scheltens P, "Qualitative assessment of cerebral atrophy on MRI : inter-and intra-observer reproducibility in dementia and normal aging", Eur Neurol, 37, pp.95~99 (1997)
- Scheltens P, "Atrophy of medial temporal lobes on MRI in"probable"Alzheimer’s disease and normal ageing : diagnostic value and neuropsychological correlates", J Neurol Neurosurg Psychiatry, 55, pp.967~972 (1992)
- Johnson KA, "Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association", J Nucl Med, 54, pp.476~490 (2013)
- Sabri O, "Beta-amyloid imaging with florbetaben", Clin Transl Imaging, 3, pp.13~26 (2015)
- McKhann G, "Clinical diagnosis of Alzheimer’s disease : report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease", Neurology, 34, pp.939~944 (1984)
- florbetaben PET study, "Neurology", 2015, 500~507
- Sabbagh MN, "Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer’s dementia", Alzheimers Dement, 11, pp.994~1004 (2015)
- Matthews DC, "Dissociation of Down syndrome and Alzheimer’s disease effects with imaging", Alzheimers Dement, 2, pp.69~81 (2016)
- Klunk WE, "Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees", J Neurosci, 27, pp.6174~6184 (2007)
- Villemagne VL, "High striatal amyloid β-peptide deposition across different autosomal Alzheimer disease mutation types", Arch Neurol, 66, pp.1537~1544 (2009)
- Wirths O, "Intraneuronal APP", A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice, 2002, pp.12, 275~286
- Pera M, "Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease", Acta Neuropathol, 125, pp.201~213 (2013)
- Shinohara M, "Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer’s disease", Brain, 137, pp.1533~1549 (2014)